SIRT Versus cTACE for Unresectable HCC (CHANCE2506)
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18+
SponsorZhongda Hospital
About this trial
To evaluate the efficacy and safety of yttrium-90 carbon microspheres versus cTACE in patients with unresectable hepatocellular carcinoma
Eligibility criteria
Qualifiers
Eastern Cooperative Oncology Group performance status ≤ 1;
Expected survival time ≥ 3 months;
Confirmed hepatocellular carcinoma based on CNLC guidelines;
Without extrahepatic metastases, unresectable or refuse surgical resection;
Disqualifiers
With previous history of hepatic encephalopathy;
Extrahepatic disease or combined with other malignant tumors;
Infiltrative hepatocellular carcinoma ;
With prior antitumor therapies, including liver transplantation, hepatectomy, ablation, TACE, chemotherapy, radiotherapy, targeted therapy or immunotherapy;
Trial design
Treatments tested in this trial
- SIRT
- cTACE
Treatment groups
108 Participants
are divided into 2 treatment groupsSponsors and collaborators
Source ClinicalTrials.gov